NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards ...

Lawsuit and Allegations - A class action lawsuit has been filed against Edwards Lifesciences Corporation for securities purchased between February 6, 2024, and July 24, 2024 [1] - The lawsuit alleges that the company provided misleading information regarding its expected revenue for fiscal year 2024, particularly related to the growth of its core product, Transcatheter Aortic Valve Replacement (TAVR) [2] - Defendants claimed strong commitment to the TAVR platform and confidence in capitalizing on untreated patients through patient activation activities [2] Financial Performance and Guidance - On July 24, 2024, Edwards reported below-expectation financial results for Q2 2024 and significantly reduced its revenue guidance for the TAVR platform for the full fiscal year [3] - The company attributed the TAVR setback to the growth and expansion of structural heart therapies, which pressured hospital workflows [3] - Investors interpreted this as new procedures, including Transcatheter Mitral and Tricuspid Therapies (TMTT), straining hospital resources and leading to underutilization of TAVR [3] Market Reaction - Following the financial revelations, Edwards' stock price dropped dramatically from $86 95 per share on July 24, 2024, to $59 70 per share on July 25, 2024, a decline of approximately 31 34% in a single day [4] Strategic Moves - During Q2 2024, Edwards announced three acquisitions aimed at strengthening treatments alternative to TAVR, suggesting the company anticipated decelerated growth in the TAVR platform [3]

Edwards Lifescience (EW, Financial), a medical device company that specializes in cardiovascular, today by soaring 6% to $68.49 per share at the time this article was written. Technical analysis suggests that it's the moment of "strong buy". The market reacted after EW received its commercial approval of their transcatheter tricuspid valve replacement (TTVR) device thanks to their TRICSEND II trial that marks a significant milestone to the company. The TRISCEND II trial was a clinical study to evaluate the ...

Edwards Lifesciences' (EW) strategic decision to divest its Critical Care segment aligns with its vision to create a comprehensive portfolio for structural heart disease. Innovations such as the RESILLIA technology enhance the performance of the company's TAVR (Transcatheter Aortic Valve Replacement) business. Additionally, progress within the TMTT (Transcatheter Mitral and Tricuspid Therapies) portfolio instils optimism. However, adverse macroeconomic impacts and currency fluctuations raise concerns for Ed ...

In my opinion, companies that have a stable position in their market and competitive advantages are an interesting investment when they face temporary problems that can be solved. And Edwards Lifesciences Corporation ( My primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for ...

Edwards Lifesciences (EW) has completed the sale of its Critical Care product group to Becton, Dickinson and Company (BDX) for $4.2 billion in an all-cash transaction. The divestiture was first announced earlier in June 2024, replacing the previous plan for a tax-free spin-off of the segment. The company will use the net proceeds from the sale to fund strategic initiatives, including the previously announced acquisitions and share repurchases. Investors' sentiment was bearish immediately after the news rele ...

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that, further to its news releases of August 16, 2024 and August 29, 2024, the special distribution to holders of common shares of the Company ("Shareholders") by way of a return of capital, in the amount of $0.03 per common share of the Company, for an aggregate distribution amount of $ 2,714,569.95 (the "Distribution"), will be paid by the Company's ...

At the European Society of Cardiology Congress 2024, Edwards Lifesciences (EW) announced the results from the RHEIA Trial — the first-ever study focused exclusively on women receiving transcatheter aortic valve implantation (TAVI). The outcome revealed that Edwards SAPIEN 3 or SAPIEN 3 Ultra valves have led to superior outcomes for women compared with those receiving surgical aortic valve replacement (SAVR). The latest development will strongly boost the company's Transcatheter Aortic Valve Replacement (TAV ...

. . . East West Petroleum Announces Cash Distribution to Shareholders by Way of Return of Capital August 29, 2024 7:00 AM EDT | Source: East West Petroleum Corp. Vancouver, British Columbia--(Newsfile Corp. - August 29, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to announce that, further to its news release of August 16, 2024, it will distribute to holders of common shares of the Company ("Shareholders") by way of a return of capital, $0.03 per common share of the ...